Search Result

Results for "

Nicotinamide+mononucleotide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Caspase (1) CXCR (2) Endogenous Metabolite (5) Flavivirus (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Liposome (1) Melanocortin Receptor (1) NAMPT (3) Neuropeptide Y Receptor (2) Parasite (1) Reference Standards (2) Toll-like Receptor (TLR) (1) Trk Receptor (1)
By Research Areas:	Cancer (9) Infection (1) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (7)
Oligonucleotides:	Liposome (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-F0004

Fosribnicotinamide 25+ Cited Publications β-Nicotinamide mononucleotide; β-NM; NMN	Endogenous Metabolite	Neurological Disease Cancer
Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD ⁺ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

HY-129522

Sulfo-ara-F-NMN 5+ Cited Publications CZ-48	Toll-like Receptor (TLR)	Neurological Disease
Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating SARM1 but inhibiting CD38 (IC₅₀ around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production .

HY-W615108B

*β-Nicotinamide mononucleotide, reduced form disodium* NMNH disodium	Endogenous Metabolite	Cancer
β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD ⁺ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .

HY-126255

SBI-797812 2 Publications Verification	NAMPT	Metabolic Disease
SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD ⁺. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD ⁺ in mice .

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-W015764

T-1105 2 Publications Verification	Flavivirus	Infection
T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase .

HY-F0004S

Fosribnicotinamide-d4 β-Nicotinamide mononucleotide-d₄; β-NM-d₄; NMN-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Cancer
Fosribnicotinamide-d₄ (β-Nicotinamide mononucleotide-d₄) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-F0004R

Fosribnicotinamide (Standard) β-Nicotinamide mononucleotide (Standard); β-NM (Standard); NMN (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease Cancer
Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard)) is the analytical standard of Fosribnicotinamide (HY-F0004 ). This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD ⁺ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

HY-177843

Liposomal NMN	Liposome	Metabolic Disease
Liposomal NMN is a specialized delivery system that encapsulates NMN within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of NMN. NMN (β-Nicotinamide Mononucleotide) is a naturally occurring key met

HY-P2940

NADase	NAMPT	Inflammation/Immunology
NADase is an ectoenzyme/membrane-bound enzyme targeting nicotinamide adenine dinucleotide (NAD ⁺). NADase regulates intracellular NAD ⁺ homeostasis by hydrolyzing NAD ⁺ into nicotinamide mononucleotide (NMN) and ADP-ribose. NADase is promising for research of autoimmune diseases (e.g., systemic sclerosis, systemic lupus erythematosus) and aging-related disorders .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-W615108BR

*β-Nicotinamide mononucleotide, reduced form disodium (Standard)*	Endogenous Metabolite Reference Standards	Cancer
β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium) (HY-W615108B). This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-119159

AS1604498	NAMPT Caspase Apoptosis	Cancer
AS1604498 is a highly specific competitive inhibitor of human NAMPT, with an IC₅₀ of 44.4 nM. AS1604498 functionally inhibits NAMPT enzymatic activity, reduces nicotinamide mononucleotide production, decreases intracellular NAD levels, activates caspase 3/7 and induces cancer cell apoptosis. AS1604498 is applicable to research related to chronic myeloid leukemia .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

Cat. No.	Product Name	Target	Research Area

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-F0004

Fosribnicotinamide 25+ Cited Publications β-Nicotinamide mononucleotide; β-NM; NMN	Human Gut Microbiota Metabolites Microorganisms Other disease Neurological Disease Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD ⁺ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

HY-W615108B

*β-Nicotinamide mononucleotide, reduced form disodium* NMNH disodium	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD ⁺ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .

HY-F0004R

Fosribnicotinamide (Standard) β-Nicotinamide mononucleotide (Standard); β-NM (Standard); NMN (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard)) is the analytical standard of Fosribnicotinamide (HY-F0004 ). This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD ⁺ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

HY-W615108BR

*β-Nicotinamide mononucleotide, reduced form disodium (Standard)*	Structural Classification Natural Products Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium) (HY-W615108B). This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .

Cat. No.	Product Name	Chemical Structure

HY-F0004S

Fosribnicotinamide-d4
Fosribnicotinamide-d₄ (β-Nicotinamide mononucleotide-d₄) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

Fosribnicotinamide-d4

Fosribnicotinamide-d₄ (β-Nicotinamide mononucleotide-d₄) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .

Cat. No.	Product Name		Classification

HY-177843

Liposomal NMN		Liposome
Liposomal NMN is a specialized delivery system that encapsulates NMN within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of NMN. NMN (β-Nicotinamide Mononucleotide) is a naturally occurring key met

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Nicotinamide+mononucleotide

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products